Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Inclusion Criteria: * Adult patients with a first episode of symptomatic, proximal DVT of the lower limbs, confirmed by Duplex Ultrasound (DUS) * Indication for treatment with Tinzaparin * Patient covered by French national health insurance, * Written informed consent. Exclusion Criteria: * Recent DVT (less than 2 months) objectively proven by venous ultrasound - Severe ilio-femoral DVT requiring recanalization * Duration of treatment of more than 24 h since diagnosis * Patients with acute symptoms (leg pain and swelling) for more than 5 days * Planned surgery in the following 3 weeks, impossible to postpone * Active haemorrhage or high risk of haemorrhage * Symptoms of Post Thrombotic Syndrome * Active neoplasm * APL syndrome * Renal insufficiency (Creatinine clearance (Cockcroft-Gault) \<20 mL/min) * Hepatic disease / or Hepatic Insufficiency / or serious liver disease * Hyperkaliemia more than 5 mmol/L * Patients with mechanical prosthetic heart valve * weight more than 105 kgs in order to avoid difficulties with a dosage of 20000UI OF TINZAPARIN Any anti-inflammatory drugs or anti-platelet therapy * Any other concomitant anticoagulant treatment such as VKA, heparin, fondaparinux and direct oral anticoagulants * Contraindications to tinzaparin according to their SmPC * Patient with asthma, If patients need to receive tinzaparin 10000UI antiX-a/0.5ml for the study,(due to sodium metabisulfite in the solution) * Pregnant women or breastfeeding * patient with age under 18 * Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)